Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice

Drug Metabolism and Disposition

Volumn 44, Issue 3, 2016, Pages 428-434

  Hartmann, Georgy ^a   Kumar, Sanjeev ^a,b   Johns, Douglas ^a   Gheyas, Ferdous ^a   Gutstein, David ^a   Shen, Xiaolan ^a   Burton, Aimee ^a   Lederman, Harmony ^a   Lutz, Ryan ^a   Jackson, Tonya ^a   Chavez Eng, Cynthia ^a   Mitra, Kaushik ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; OXAZOLIDINONE DERIVATIVE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD; BRAIN; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DIET INDUCED OBESITY; DNA FLANKING REGION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TISSUE LEVEL; HUMAN; IN VIVO STUDY; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OBESITY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TISSUE LEVEL; TRANSGENIC MOUSE; TREATMENT DURATION; TREND STUDY; WESTERN DIET; WHITE ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DIET; KINETICS; METABOLISM;

ADIPOSE TISSUE; ANIMALS; CHOLESTEROL ESTER TRANSFER PROTEINS; DIET; KINETICS; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; OXAZOLIDINONES;

EID: 84958964753     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.067736     Document Type: Article

References (19)

1. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, and Waters DD, et al.; ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122.
2. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, 3rd, Sisk CM, Mitchel Y, and Pasternak RC (2009) Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 157:352-360.
3. Gotto AM, Jr, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, Davidson M, Moon JE, Shah S, and Dansky HM, et al. DEFINE Investigators (2014a) Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol 113:76-83.
4. Gotto AM, Jr, Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, Cannon CP, Brinton EA, Moon JE, and Shah S, et al. DEFINE Investigators (2014b) Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. J Cardiovasc Pharmacol Ther 19:543-549.
5. Gutstein DE, Krishna R, Johns D, Surks HK, Dansky HM, Shah S, Mitchel YB, Arena J, and Wagner JA (2012) Anacetrapib, a novel CETP inhibitor: Pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther 91:109-122.
6. Jeon H, Lee S, Kim TE, Yoon SH, Shin SG, Jang IJ, and Yu KS (2011) Pharmacokinetics and tolerability of probucol after multiple oral administrations in healthy volunteers. Int J Clin Pharmacol Ther 49:688-695.
7. Jiang XC, Agellon LB, Walsh A, Breslow JL, and Tall A (1992) Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 90:1290-1295.
8. Krishna R, Bergman AJ, Jin B, Fallon M, Cote J, Van Hoydonck P, Laethem T, Gendrano IN, 3rd, Van Dyck K, and Hilliard D, et al. (2008) Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 84:679-683.
9. Li T, Owsley E, Matozel M, Hsu P, Novak CM, and Chiang JY (2010) Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 52:678-690.
10. Linsel-Nitschke P and Tall AR (2005) HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4:193-205.
11. Masucci-Magoulas L, Moulin P, Jiang XC, Richardson H, Walsh A, Breslow JL, and Tall A (1995) Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. J Clin Invest 95:1587-1594.
12. Nicholls SJ, Lincoff AM, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Grainger C, Menon V, Montalescot G, and Rader D, et al. (2015) Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. Am Heart J 170: 1061-1069.
13. Roddy TP, McLaren DG, Chen Y, Xie D, Dunn K, Kulick A, Szeto D, Forrest G, Albanese K, and Donnelly M, et al. (2014) Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques. Eur J Pharmacol 740:410-416.
14. Saely CH, Geiger K, and Drexel H (2012) Brown versus white adipose tissue: A mini-review. Gerontology 58:15-23.
15. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, and Leiter LA, et al.; dal-OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089-2099.
16. Tall AR (2007) CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 356: 1364-1366.
17. Tan EY, Hartmann G, Chen Q, Pereira A, Bradley S, Doss G, Zhang AS, Ho JZ, Braun MP, and Dean DC, et al. (2010) Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab Dispos 38:459-473.
18. Tuteja S and Rader DJ (2014) High-density lipoproteins in the prevention of cardiovascular disease: ChAnGiNg tHe paradigm. Clin Pharmacol Ther 96:48-56.
19. Vadiei K, Troy S, Korth-Bradley J, Chiang ST, and Zimmerman JJ (1997) Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. J Clin Pharmacol 37:610-617.